The Neurosurgery Signal — Signal, Not Noise

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1016/S1474-4422(10)70093-4

PMID

20434403

PICO

Population

Patients with advanced Parkinson's disease not adequately controlled by medical therapy

Intervention

Immediate surgery (deep brain stimulation or lesioning) plus best medical therapy

Comparator

Best medical therapy alone

Outcomes

Self-reported quality of life (PDQ-39), motor function (UPDRS), adverse events

Design

Type

Randomized controlled trial

Randomized

Yes

Multicenter

Yes

Blinded

Open-label

Follow-up

1 year (planned up to 9 years)

Primary endpoint

Change in PDQ-39 summary index score from baseline to 1 year

Secondary endpoints

PDQ-39 domain scores
UPDRS scores
Adverse events

Practice impact

What this means

This UK multicenter RCT compared DBS plus medical therapy versus medical therapy alone in 366 advanced Parkinson's patients. At 1 year, DBS improved PDQ-39 quality of life scores by 4.7 points more than medical therapy alone, with significant benefits in mobility, ADL, and bodily discomfort domains. However, 19% had serious surgery-related adverse events including one death. DBS provides meaningful quality of life improvement but requires careful patient selection given surgical risks.

Bottom line

DBS plus medical therapy improves quality of life more than medical therapy alone in advanced Parkinson's disease, but with significant surgical risks

Strength of evidence

moderate

Recommendation

consider change

Why it matters

Randomized trial with 366 patients
Clinically meaningful improvement in PDQ-39 summary index and key domains
19% serious surgery-related adverse events including one procedure-related death

What would change my mind

Longer-term follow-up showing durability of benefit
Blinded assessment of motor outcomes
Cost-effectiveness analysis
Subgroup analysis identifying patients with greatest benefit-risk ratio

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Open-label design introduces performance and detection bias; randomization with minimization balanced baseline characteristics

Confounding

Minimization procedure controlled for age, disease duration, Hoehn and Yahr stage, reason for surgery, and planned surgical/drug approach

Missing data

Patients without 1-year follow-up excluded from analysis; missing PDQ-39 domain scores imputed using expectation maximization algorithm

Multiplicity

Multiple secondary endpoints analyzed without adjustment; subgroup analyses by stratification parameters performed

Notes

All surgery patients received DBS despite protocol allowing lesioning
Crossover allowed after 1 year in medical therapy group

Stats check

NNT

N/A

Effect sizes

Mean difference in PDQ-39 summary index: -4.7 points (95% CI -7.6 to -1.8)
Mean difference in PDQ-39 mobility domain: -8.9 (95% CI -13.8 to -4.0)
Mean difference in PDQ-39 ADL domain: -12.4 (95% CI -17.3 to -7.5)

Absolute effects

366 patients randomized (183 per group)
Mean PDQ-39 improvement: 5.0 points in surgery group vs 0.3 points in medical group
36 patients (19%) had serious surgery-related adverse events

Concerns

Open-label design may influence patient-reported outcomes
Multiple secondary endpoints without multiplicity adjustment

External validity

Who it applies to

Advanced Parkinson's disease patients with inadequate medical control, similar to UK trial population (mean age 59, mean disease duration 11.4 years)

Who it does not

Patients with dementia (DRS-II score ≤5 excluded), those unfit for surgery, early Parkinson's disease

Generalizability notes

13 UK neurosurgical centers
All surgery patients received DBS (subthalamic nucleus or GPi)
Medical therapy optimized per local practice

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 2 Methods

quote

The PD SURG trial is an ongoing randomised, open-label trial.

claim_id

stats_check.effect_sizes

locator

p. 3 Results

quote

At 1 year, the mean improvement in PDQ-39 summary index score compared with baseline was 5·0 points in the surgery group and 0·3 points in the medical therapy group (difference −4·7, 95% CI −7·6 to −1·8; p=0·001)

claim_id

practice_impact.bottom_line

locator

p. 4 Interpretation

quote

At 1 year, surgery and best medical therapy improved patient self-reported quality of life more than best medical therapy alone in patients with advanced Parkinson's disease. These differences are clinically meaningful, but surgery is no...

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years